CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
CCTG would like to note, with sorrow, the recent death of Dr. Paul Goss and to recognize his contributions to the Group.
CCTG’s Tumour Tissue Data Repository (TTDR) has now moved into its new home at Kingston Health Sciences Centre (KHSC), a highly anticipated state-of-the-art space designed to support and advance the future of cancer research.
The TTDR expansion supports the group’s capacity for ongoing and new initiatives. The refurbished area includes a larger centralized capacity for genomic, transcriptomic and proteomic studies that will leverage expertise among member sites.
The CCTG Annual Spring Meeting of Participants will be held Friday, April 24 to Sunday, April 26 at the Chelsea Hotel in Toronto. Additionally, there are Workshops being held on Thursday, April 23, which are closed and by invitation only. These workshops will require a separate invitation and registration, and attendees invited to a Workshop in addition to the Spring Meeting must register for both.
Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial
